# Parkervision Inc: Form 10-Q for the period ended Jun 30, 2019

- Company: [Parkervision Inc](/companies/prkr.md) (CIK 914139)
- Form: 10-Q
- Filed: 2019-08-14
- Accepted by EDGAR: Aug 14, 2019, 16:30 ET
- Period: 2019-06-30
- Accession: 0001654954-19-009588
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/914139/000165495419009588/prkr_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/914139/000165495419009588/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-04-01 to 2019-06-30 | $25.0k | us-gaap:Revenues |
| Revenue | 6 months, 2019-01-01 to 2019-06-30 | $35.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-04-01 to 2019-06-30 | $25.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2019-01-01 to 2019-06-30 | $35.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-04-01 to 2019-06-30 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months, 2019-01-01 to 2019-06-30 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-04-01 to 2019-06-30 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-01-01 to 2019-06-30 | $334.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-04-01 to 2019-06-30 | $1.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2019-01-01 to 2019-06-30 | $4.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2019-04-01 to 2019-06-30 | $76.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2019-01-01 to 2019-06-30 | $138.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2019-04-01 to 2019-06-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-01-01 to 2019-06-30 | −$3.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-04-01 to 2019-06-30 | −$0.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2019-01-01 to 2019-06-30 | −$0.12 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2019-04-01 to 2019-06-30 | −$877.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 6 months, 2019-01-01 to 2019-06-30 | −$2.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-04-01 to 2019-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Capital expenditure | 6 months, 2019-01-01 to 2019-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-06-30 | $63.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-06-30 | $809.0k | us-gaap:AssetsCurrent |
| Total assets | at 2019-06-30 | $4.6m | us-gaap:Assets |
| Current liabilities | at 2019-06-30 | $5.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-06-30 | $33.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-06-30 | −$28.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 24,475 characters.

#### Forward-Looking Statements

We believe that it is important to communicate our future expectations to our shareholders and to the public. This quarterly report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, in particular, statements about our future plans, objectives, and expectations contained in this Item. When used in this quarterly report and in future filings by us with the Securities and Exchange Commission (“SEC”), the words or phrases “expects”, “will likely result”, “will continue”, “is anticipated”, “estimated” or similar expressions are intended to identify “forward-looking statements.” Readers are cautioned not to place undue reliance on such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and those presently anticipated or projected, including the risks and uncertainties identified in our annual report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 Annual Report”) and in this Item 2 of Part I of this quarterly report. Examples of such risks and uncertainties include general economic and business conditions, competition, unexpected changes in technologies and technological advances, the timely development and commercial acceptance of new products and technologies, reliance on key suppliers, reliance on our intellectual property, the outcome of our intellectual property litigation and the ability to obtain adequate financing in the future. We have no obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect anticipated events or circumstances occurring after the date of such statements.

#### Corporate Website

We announce investor information, including news and commentary about our business, financial performance and related matters, SEC filings, notices of investor events, and our press and earnings releases, in the investor relations section of our website (http://www.parkervision.com/investor-relations). Investors and others can receive notifications of new information posted in the investor relations section in real time by signing up for email alerts and/or RSS feeds. Further corporate governance information, including our governance guidelines, board committee charters, and code of conduct, is also available in the investor relations section of our website under the heading “Corporate Governance.” The content of our website is not incorporated by reference into this quarterly report or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.

#### Overview

We are in the business of innovating fundamental wireless technologies and products. We have designed and developed proprietary RF technologies and integrated circuits for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the U.S. and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore our business plan includes enforcement of our intellectual property rights through patent infringement litigation and licensing efforts. We have also designed and developed a consumer distributed WiFi product line that is being marketed under the brand name Milo.

We restructured our operations during the third quarter of 2018 in order to reduce operating expenses in light of our limited capital resources. Our primary business strategy is to support the investments we have made in developing and protecting our technologies by focusing on our patent enforcement program. We have made significant investments in developing and protecting our technologies and products, the returns on which are dependent upon the generation of future revenues for realization. We expect to sell or otherwise exit the Milo product operations in the third quarter of 2019 and intend to focus our resources solely on licensing and enforcement of our wireless technologies. During the second quarter of 2019, we ceased all research and development efforts and, where applicable, repurposed resources to support our patent enforcement and Milo sales and support efforts.

#### Recent Developments

#### Legal Proceedings

In April 2019, the district court in Munich, Germany issued a ruling in *ParkerVision v. Apple II* that the Apple products do not infringe our ‘853 Patent. We have opted not to appeal this decision. In addition, in July 2019, we withdrew our January 2019 appeal to the German Supreme Court in the *Qualcomm v. ParkerVision* nullity action which will result in dismissal of our infringement cases against Apple (*ParkerVision v. Apple I*) and LG (*ParkerVision v. LG Electronics).* We have accrued approximately $0.4 million for estimated statutory court costs that may be assessed against us in these cases. Approximately 45% of these estimated losses will be covered by bonds that we have posted in these cases.

In July 2019, the district court for the Middle District of Florida (Orlando division) issued a ruling denying Qualcomm’s request to limit the claims and patents in *ParkerVision v. Qualcomm and HTC*. The court also agreed that we may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay. A trial date of December 2020 has been proposed by the parties.

In July 2019, the district court in the Middle District of Florida (Jacksonville division) issued its claim construction order in *ParkerVision v. Apple and Qualcomm* which has been pending since an August 31, 2018 claim construction hearing. The court’s claim construction order adopted our proposed construction for two of the six disputed terms and the “plain and ordinary meaning” on the remaining terms. In addition, the court denied Apple’s motion for summary judgement.

Refer to Note 11 in the condensed consolidated financial statements for a discussion of the background of these and other pending patent litigation.

#### Debt Financings

In February and March 2019, we sold an aggregate of $1.3 million in convertible promissory notes to accredited investors. In June 2019 we sold an additional $0.3 million in convertible promissory notes to accredited investors. The notes are convertible, at the option of the holder, into shares of our common stock at a fixed conversion price of $0.25 per share for the February and March notes and $0.10 per share for the June notes. The notes pay interest quarterly at a rate of 8% per annum and we may elect to pay such interest in cash or shares, subject to certain equity conditions. In addition, in May and June 2019, we entered into short-term promissory notes with accredited investors for aggregate proceeds of approximately $0.23 million. The notes are unsecured, bear interest at a rate of 18% per annum, and mature at the earlier of 90 days following the issuance date or upon our receipt of additional litigation financing. Refer to Note 9 to the condensed consolidated financial statements for a complete discussion of the terms of these financings.

In addition, in July 2019, we sold convertible notes for aggregate proceeds of $0.75 million to accredited investors. The first tranche of notes with a face value of $0.05 million is convertible, at the holders’ option, into shares of our common stock at a fixed conversion price of $0.10 per share and bear interest at a stated rate of 8% per annum. The second tranche of notes with an aggregate face value of $0.7 million is convertible, at the holders’ option, into shares of our common stock at $0.08 per share and bear interest at a stated rate of 7.5% per annum.

#### Consulting Agreements

In June 2019, we entered into a consulting agreement with Mark Fisher to act as special advisor to our chief executive officer with regard to our future business strategies. As consideration for services provided under the six-month term of the agreement, we issued 625,000 shares of common stock, valued at approximately $0.06 million, as a nonrefundable retainer. In July 2019, we engaged an additional consultant, Park Consultants LLC ("Park"), to act in an advisory capacity over an 18-month term. As consideration for services, we granted Park a warrant for the purchase of 1.8 million shares of our common stock at an exercise price of $0.10 per share, valued at approximately $0.2 million, as a nonrefundable retainer. The warrant is immediately exercisable and expires in July 2024.

#### Share-based Compensation

In August 2019, our board of directors ("Board") adopted the 2019 Long-term Incentive Plan (the "2019 Plan") to enable us to offer equity-based compensation to our employees, officers, directors and consultants who have been, are, or will be important to our success. Subject to authorization of sufficient shares for issuance by our stockholders, 12 million shares will be reserved for issuance under the 2019 Plan. In addition, the Board authorized the grant of two-year nonqualified stock options, with an exercise price of $0.17 per share, vesting in 8 equal quarterly installments commencing September 1, 2019, provided that such options shall not be exercisable unless or until we have sufficient authorized unissued shares or treasury shares available for such exercise. Each of our three non-employee directors were granted an option to purchase 800,000 shares, Jeffrey Parker, our chief executive officer, was granted an option to purchase 6,000,000 shares, Cynthia Poehlman, our chief financial officer, was granted an option to purchase 1,000,000 shares, Gregory Rawlins, our chief technical officer, was granted an option to purchase 750,000 shares and one additional key employee was granted an option to purchase 400,000 shares. The aggregate grant-date fair value of the awards, totaling approximately $1.5 million, will be recognized as share-based compensation expense over the two-year life of the awards.

#### Liquidity and Capital Resources

We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from debt and equity financings to fund our operations, including the cost of litigation. We used cash for operations of approximately $2.6 million and $6.1 million for the six months ended June 30, 2019 and 2018, respectively. At June 30, 2019, we had a working capital deficit of approximately $4.2 million and we had an accumulated deficit of approximately $396.0 million. These circumstances raise substantial doubt about our ability to continue to operate as a going concern within one year following the issue date of our condensed consolidated financial statements. The $3.5 million decrease in cash used for operations year over year is primarily the result of the restructuring of our operations in the third quarter of 2018 and ongoing cost reduction measures.

For the six months ended June 30, 2019, we received aggregate net proceeds of approximately $1.64 million in proceeds from the sale of convertible promissory notes and $0.23 million for the issuance of short-term notes. Of these proceeds, $0.15 million was used for retention payments to legal counsel engaged to assist in a wide range of activities that include our past, current and potential future litigation actions. The remaining proceeds were used to fund our operations

At June 30, 2019, we had cash and cash equivalents of approximately $0.1 million. Our Milo product line has not generated expected revenues to date and the amount and timing of proceeds from our patent enforcement actions, if any, is difficult to predict. Although we have made significant reductions in our operating costs, we will need additional working capital to fund our operations and meet our debt repayment obligations.

In July 2019, we sold additional convertible notes for aggregate proceeds of $0.75 million. We are exploring additional financing opportunities for both our short and long-term capital needs. These financing opportunities may include debt, convertible debt, common or preferred equity offerings, additional litigation financing, or a combination thereof. There can be no assurance that we will be able to consummate a financing transaction or that the terms of such financing will be on terms and conditions that are acceptable.

Our ability to meet our short-term liquidity needs, including our debt repayment obligations, is dependent upon one or more of (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations to Brickell and legal counsel; and/or (ii) our ability to raise additional capital from the sale of equity securities or other financing arrangements.

Patent enforcement litigation is costly and time-consuming and the outcome is difficult to predict. We expect to continue to invest in the support of our patent enforcement and licensing programs. We expect that revenue generated from patent enforcement actions and/or technology licenses in 2019, if any, after deduction of payment obligations to Brickell and legal counsel, may not be sufficient to cover our operating expenses. In the event we do not generate revenues, or other patent-related proceeds, sufficient to cover our operational costs and contingent repayment obligation, we will be required to raise additional working capital through the sale of equity securities or other financing arrangements.

The long-term continuation of our business plan is dependent upon our ability to secure sufficient financing to support our business, and our ability to generate revenues and/or patent-related proceeds sufficient to offset expenses and meet our contingent payment obligation and other long-term debt repayment obligations. Failure to generate sufficient revenues, raise additional capital through debt or equity financings, and/or reduce operating costs could have a material adverse effect on our ability to meet our short and long-term liquidity needs and achieve our intended long-term business objectives.

#### Results of Operations for Each of the Three and Six Months Ended June 30, 2019 and 2018

### Revenue and Gross Margin

We reported no licensing revenue for the three and six-month periods ended June 30, 2019 or 2018. Although we do anticipate licensing revenue and/or settlement gains to result from our licensing and patent enforcement actions, the amount and timing is highly unpredictable and there can be no assurance that we will achieve our anticipated results.

We reported product revenue of approximately $0.03 million and $0.04 million for the three and six-month periods ended June 30, 2019, respectively, and $0.04 million and $0.12 million for the three and six-month periods ended June 30, 2018, respectively, from sales of our Milo-branded WiFi products. Gross margins for the Milo product sales, before inventory impairment charges, were 0% and 18%, respectively, for the three months ended June 30, 2019 and 2018 and 0% and 27%, respectively, for the six months ended June 30, 2019 and 2018. The decrease in product margins, before inventory impairment charges, is the result of reduced selling prices. Our revenues from Milo products to date have fallen short of our projections, and we have limited resources to deploy toward increasing consumer awareness of our products. As a result, we expect to sell or otherwise dispose of the Milo product line in 2019.

### Research and Development Expenses

Research and development expenses consist primarily of engineering and related management and support personnel costs; fees for outside engineering design services which we use from time to time to supplement our internal resources; depreciation expense related to our assets used in product development; prototype production and materials costs; software licensing and support costs, which represent the annual licensing and support maintenance for engineering design and other software tools; and rent and other overhead costs. Personnel costs include share-based compensation amounts which have been determined based on the grant date fair value of equity-based awards to our employees and then recorded to expense over the vesting period of the award. Subsequent to March 31, 2019, we halted all research and development efforts and, where applicable, repurposed prior engineering resources to support our patent enforcement programs or our Milo sales and support.

Our research and development expenses decreased approximately $1.0 million, or 100.0%, during the three months ended June 30, 2019 when compared to the same three-month period in 2018. The decrease is primarily the result of a $0.5 million reduction in personnel costs and a $0.1 million decrease in outside consulting fees as a result of the Milo product cost reduction measures since the third quarter of 2018. Additionally, research and development expenses decreased approximately $0.2 million due to personnel and related costs being repurposed for selling, general and administrative purposes including litigation support and Milo sales and support.

Our research and development expenses decreased approximately $1.5 million, or 82.2%, during the six months ended June 30, 2019 when compared to the same period in 2018. This decrease is primarily the result of a $0.9 million reduction in personnel costs, including a $0.1 million decrease in share-based compensation expense, and a $0.2 million decrease in consulting fees. Additionally, research and development expenses decreased approximately $0.2 million due to personnel being repurposed for selling, general and administrative purposes including litigation support and Milo sales and support.

The reductions in personnel costs for the three and six month periods is a result of the closure of our Lake Mary design facility in the third quarter of 2018 along with reductions in engineering executive and key employee compensation during that same period. The reduction in consulting fees for the three and six month periods is the result of cost reduction efforts pertaining to our Milo product operations commencing in the third quarter of 2018.

### Selling, General, and Administrative Expenses

Selling, general and administrative expenses consist primarily of executive, director, sales and marketing, and finance and administrative personnel costs, including share-based compensation, and costs incurred for advertising, insurance, shareholder relations and outside legal and professional services, including litigation expenses.

Our selling, general and administrative expenses decreased by approximately $1.1 million, or 36.2%, during the three months ended June 30, 2019 when compared to the same period in 2018. This is primarily the result of a $0.6 million decrease in personnel and related costs, including a decrease in share-based compensation expense of approximately $0.2 million, a decrease in marketing and other business consulting fees of approximately $0.2 million, and decreases in noncash amortization expense, travel costs, board compensation, and Milo product advertising costs of approximately $0.1 million each. These decreases are partially offset by a loss recognized on the disposal of certain patent assets of approximately $0.2 million.

Our selling, general and administrative expenses decreased by approximately $1.9 million, or 31.8%, during the six months ended June 30, 2019 when compared to the same period in 2018. This is primarily due to a $1.3 million decrease in personnel and related expense, including a decrease in share-based compensation expense of approximately $0.5 million, a decrease in marketing and other consulting fees of approximately $0.5 million, a decrease in noncash amortization expense of approximately $0.2 million, a decrease in travel costs and board compensation of approximately $0.1 million each, and a decrease in Milo product advertising costs of approximately $0.4 million. These decreases are somewhat offset by a loss on disposal of certain patents of approximately $0.2 million, and an increase in litigation-related fees and expenses of approximately $0.8 million.

The decrease in personnel costs for the three and six-month periods ended June 30, 2019 is primarily the result of the reduction in personnel and executive compensation as part of our recent cost reduction measures, somewhat offset by the repurposing of engineering personnel for litigation support and Milo sales support. Share-based compensation expense decreased for both the three and six month periods during 2019 when compared to the same periods in 2018 as a result of lower stock prices and longer vesting periods for new awards when compared to prior year awards. The decreases in our marketing consulting fees, travel costs and Milo product advertising for both the three and six month periods is a result of our cost reduction measures that commenced in the third quarter of 2018.

The decrease in noncash amortization expense for the three and six month periods ended June 30, 2019 is the result of the expiration and/or abandonment of a number of our patents and patent applications since the third quarter of 2018.

The decrease in board compensation for the three and six month periods ended June 30, 2019 is a result of our board restructuring in the third quarter of 2018 and the waiver of any cash fees for board or committee service by our nonemployee directors.

The increase in litigation related fees and expenses for the six months ended June 30, 2019 is primarily the result of fees and expenses incurred to support our German litigation, including accruals for statutory court costs as a result of unfavorable court decisions.

### Change in Fair Value of Contingent Payment Obligation

We have elected to measure our secured contingent payment obligation at fair value which is based on significant unobservable inputs. We estimated the fair value of our secured contingent payment obligation using an income approach based on the estimated present value of projected future cash outflows using a risk-adjusted discount rate. Increases or decreases in the significant unobservable inputs could result in significant increases or decreases in fair value.

For the three and six months ended June 30, 2019, we recorded decreases in the fair value of our secured contingent payment obligation of approximately $0.4 million and $0.8 million, respectively compared to increases in fair value of approximately $0.5 million and $1.0 million for the same periods in 2018. The changes in fair value are a result of changes in estimated amounts and timing of projected future cash flows due to increases in funded amounts, passage of time, and changes in the probabilities based on the status of the funded actions.

#### Off-Balance Sheet Transactions, Arrangements and Other Relationships

As of June 30, 2019, we had outstanding warrants to purchase approximately 11.7 million shares of our common stock, including pre-funded warrants to purchase 1.4 million shares of our common stock at an exercise price of $0.01 per share. The estimated grant date fair value of these warrants of approximately $1.5 million is included in shareholders’ deficit in our condensed consolidated balance sheets. The outstanding warrants have a weighted average exercise price of $0.45 per share and a weighted average remaining life of approximately 4.2 years.

#### Contractual Obligations

Changes to our contractual obligations from those included in our 2018 Annual Report are discussed in Note 9 to our unaudited condensed consolidated financial statements included in this quarterly report, which discussion is incorporated herein by reference.

#### Critical Accounting Policies

Changes to our critical accounting policies from those stated in our 2018 Annual Report are discussed in the section entitled “Adoption of New Accounting Standards” in Note 4 to our unaudited condensed consolidated financial statements included in this quarterly report, which discussion is incorporated herein by reference.

## Controls and procedures

As filed, 943 characters.

#### Evaluation of Disclosure Controls and Procedures

As of June 30, 2019, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures,” as defined in Rule 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of June 30, 2019.

#### Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 395 characters.

There have been no material changes from the risk factors disclosed in Item 1A of Part I of our Annual Report. In addition to the information in this quarterly report, the risk factors disclosed in our Annual Report should be carefully considered in evaluating our business because such factors may have a significant impact on our business, operating results, liquidity and financial condition.

Filed Aug 14, 2019.
Source: SEC EDGAR, the filing index for accession 0001654954-19-009588. Last ingested by Listed: Nov 11, 2026, 01:56 ET. No prices; not investment advice.
